BioSpace News Archive

An application for listing on the U.S. Nasdaq Stock Market for the shares of Allarity Therapeutics, Inc. (Delaware) (Nasdaq: ALLR) has been made conditioned upon shareholder approval of the Company’s Recapitalization Share Exchange

ICON plc today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at: the 30th Annual Credit Suisse Healthcare Conference on Tuesday, November 9, 2021 at 8.50am ET

Reven Holdings, Inc. today announced the publication of a peer-reviewed article in the prestigious medical journal Frontiers in Oncology.

Applied DNA Sciences, Inc. stand ready to help large employers prepare for compliance with the federally directed OSHA Emergency Temporary Standard (“ETS”) with a turnkey and cost-effective integrated offering to efficiently track employee COVID-19 vaccination status

Citius Pharmaceuticals, Inc. today announced the appointment of pharmaceutical industry veteran Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls (CMC).

Each Unit is comprised of one Class A common share of the Company (each, a “Unit Share”) and one-half of one Class A common share purchase warrant of the Company (each, a “Warrant”).

Cyclacel Pharmaceuticals, Inc. announced dosing of the first patient in the Company’s multi-cohort Phase 1/2 study of oral fadraciclib in patients with leukemias or myelodysplastic syndromes (MDS).

AbbVie (NYSE: ABBV) today announced the presentation of integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating the efficacy and safety of risankizumab (SKYRIZI®) in adult patients with active psoriatic arthritis (PsA).

Medtronic plc, a global leader in healthcare technology, unveiled five-year clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation Trial, which was presented as a Late Breaking Clinical Trial at the 33rd Transcatheter Cardiovascular Therapeutics conference, the annual scientific symposium of the Cardiovascular Research Foundation.

Edwards Lifesciences (NYSE: EW) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (TAVR) to surgery demonstrated that TAVR with SAPIEN 3 is an economically dominant treatment strategy, offering improved outcomes and reduced cost.